2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Seethamraju H, Yang O, Loftus R, Ogbuagu O, Sammartino D, Mansour A, Sacha J, Ojha S, Hansen S, Arman A, Lalezari J. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19. Clinical Therapeutics 2024, 46: 891-899. PMID: 39353749, DOI: 10.1016/j.clinthera.2024.08.019.Peer-Reviewed Original ResearchMild to moderate COVID-19National Early Warning Score 2SARS-CoV-2 infectionPost hoc analysisSARS-CoV-2Randomized placebo-controlled trialHoc analysisHuman IgG4 monoclonal antibodyModerate-to-severe diseaseViral replicationHIV-1 infectionPlacebo-controlled studyProduction of pro-inflammatory cytokinesExcessive production of pro-inflammatory cytokinesMild-to-moderateAdverse event ratesExploratory post hoc analysisTotal symptom scorePathophysiology of SARS-CoV-2 infectionPro-inflammatory cytokinesHeightened immune responsePathophysiology of COVID-19IgG4 monoclonal antibodyPlacebo groupDouble-blindAnalysis of drug–drug interactions in patients with HIV and metabolic syndrome
Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug–drug interactions in patients with HIV and metabolic syndrome. Expert Opinion On Drug Metabolism & Toxicology 2024, 20: 953-965. PMID: 39230187, DOI: 10.1080/17425255.2024.2401044.Peer-Reviewed Original ResearchDrug-drug interactionsAntiretroviral therapyMetabolic disordersMetabolic syndromeNanotechnology-based drug delivery platformsPrevalence of metabolic comorbiditiesSelection of antiretroviral therapyLong-acting antiretroviral therapyContemporary antiretroviral therapyEffective antiretroviral therapyPrevalence of metabolic disordersRepertoire of treatment optionsDrug-drug interaction dataTreat metabolic syndromeMetabolic comorbiditiesTreatment optionsDrug delivery platformPrescribing informationAnalysis of drug-drug interactionsHIVInjectable medicationsDrug prescribing informationWeight lossPWHSyndromeEfficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial
Ogbuagu O, Molina J, Chetchotisakd P, Ramgopal M, Sanchez W, Brunetta J, Castelli F, Crofoot G, Hung C, Ronot-Bregigeon S, Margot N, Wang H, Dvory-Sobol H, Rhee M, Segal-Maurer S. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases 2024, ciae423. PMID: 39206943, DOI: 10.1093/cid/ciae423.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1Optimized background regimenHIV-1 RNA <CD4 cell countHIV-1Food & Drug AdministrationAdverse eventsTreatment of HIV-1 infectionRates of virologic suppressionCD4 cell count <Treatment-related adverse eventsMulti-drug resistant HIV-1Cell countTreatment-experienced peopleCell count <HIV-1 infectionHIV-1 RNAPhase 2/3 trialsImportant treatment optionInjection site reactionsResistant HIV-1US Food & Drug AdministrationBackground regimenVirologic suppressionStudy drug
2023
Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study
Strong S, Oldfield B, van den Berg J, Cole C, Biegacki E, Ogbuagu O, Virata M, Chan P, Edelman E. Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study. Preventive Medicine Reports 2023, 37: 102553. PMID: 38282665, PMCID: PMC10810836, DOI: 10.1016/j.pmedr.2023.102553.Peer-Reviewed Original ResearchUnhealthy alcohol usePre-exposure prophylaxisAlcohol reduction interventionsAlcohol useHIV pre-exposure prophylaxisOral pre-exposure prophylaxisAcquisition of HIVAlcohol-related harmPrEP adherencePrEP careTreatment optionsOral formulationReduction interventionsPrEP programMSMPrEPProphylaxisHIVMultimodal approachMenCareAdherenceInterventionSexUnited StatesOutcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
Tuan J, Sharma M, Kayani J, Davis M, McManus D, Topal J, Ogbuagu O. Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). BMC Infectious Diseases 2023, 23: 258. PMID: 37101135, PMCID: PMC10130811, DOI: 10.1186/s12879-023-08198-9.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsPregnant womenClinical outcomesEmergency departmentPositive SARS-CoV-2 testAdverse feto-maternal outcomesIntensive care unit admissionMild-moderate COVID-19Pregnant COVID-19 patientsPrimary composite clinical outcomeSARS-CoV-2 testComplete primary vaccinationComposite clinical outcomeCare unit admissionFeto-maternal outcomeMedical record reviewSARS-CoV-2 treatmentBetter clinical outcomesBody mass indexSickle cell diseaseCOVID-19SARS-CoV-2Neonatal complicationsPrimary vaccinationUnit admissionLenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options
Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.Peer-Reviewed Original ResearchConceptsTreatment optionsMultidrug-resistant HIV infectionMultidrug-resistant HIVTreatment-emergent resistanceLimited treatment optionsClinical trial dataDrug-drug interactionsBreakthrough therapy designationHIV-1 capsid inhibitorsMechanism of actionAdherence supportCompanion drugsAntiretroviral agentsHIV infectionHIV treatmentClinical trialsLenacapavirPharmacodynamic propertiesDrug AdministrationExpert opinion sectionCapsid inhibitorsTrial dataU.S. FoodClinical usesYearly treatmentCorrection: HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. Correction: HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 224. PMID: 37046201, PMCID: PMC10100465, DOI: 10.1186/s12879-023-08159-2.Peer-Reviewed Original ResearchHIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report
Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 146. PMID: 36890468, PMCID: PMC9993362, DOI: 10.1186/s12879-023-08075-5.Peer-Reviewed Original ResearchConceptsHIV risk profilesSTI riskPre-exposure prophylaxis useRisk profileMedian age 28 yearsHIV-negative respondentsHIV-negative participantsHIV-negative individualsReceptive anal intercourseModerate alcohol useAge 28 yearsCross-sectional surveySexual partner numberProphylaxis useResultsEighty-onePrEP knowledgeHIV positivityPrevention gapUrban clinicCenter clinicPrevention needsSTI historyInclusion criteriaAnal intercourseIllicit substances
2022
Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report
Tuan J, Ogbuagu O, Kumar D, Altice F, Fikrig M. Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. Journal Of Medical Case Reports 2022, 16: 491. PMID: 36578087, PMCID: PMC9795945, DOI: 10.1186/s13256-022-03721-z.Peer-Reviewed Case Reports and Technical NotesConceptsAcute kidney injuryCoronavirus disease 2019Kidney injuryDisease 2019Cast nephropathyEnd-organ damageRenal biopsy findingsSpectrum of diseaseBaseline 6Gastrointestinal symptomsHospital courseBiopsy findingsCase presentationAPoor appetiteRenal failureRenal functionOral intakeUrine outputInitial diagnosisCaucasian manCase reportRhabdomyolysisNephropathyAbnormal tasteOrgan systemsLong-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Early infant diagnosis of HIV infection at the John F. Kennedy Medical Center, Monrovia, Liberia
I U U, Adeiza M, Ideh R, Ogbuagu O. Early infant diagnosis of HIV infection at the John F. Kennedy Medical Center, Monrovia, Liberia. HIV Research & Clinical Practice 2022, 23: 136-140. PMID: 35703420, DOI: 10.1080/25787489.2022.2086093.Peer-Reviewed Original ResearchConceptsVertical transmission rateVertical transmissionMTCT programmePCR testingEarly infant diagnosis programHIV DNA PCR testingRetrospective cross-sectional analysisDemographics of mothersDNA PCR testingExpansion of preventionHIV DNA PCRHIV-positive childrenHIV-positive mothersInfectious disease clinicPost-exposure prophylaxisEarly neonatal deathNew HIV infectionsMode of deliveryLogistic regression analysisBinomial logistic regression analysisCross-sectional analysisPMTCT programmeCaesarean sectionExclusive breastfeedingDisease clinicProactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.Peer-Reviewed Original ResearchConceptsClinical trialsHIV incidencePre-exposure prophylaxis clinical trialHispanic/LatinxRecruitment goalsGood participatory practice guidelinesOngoing phase 3 trialsHIV pre-exposure prophylaxisTransgender womenTransgender menPhase 3 trialPre-exposure prophylaxisCommunity-based clinicsFuture clinical trialsClinical trial numberEvidence-informed recommendationsLatinx MSMGender nonbinary individualsCisgender MSMNovel agentsPractice guidelinesStudy populationBlack MSMUS sitesTrialsDe novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVirologic responsePersistent SARS-CoV-2 infectionResistance mutationsPre-treatment specimensB-cell deficiencyRemdesivir resistanceRemdesivir therapyViral sheddingCase reportAntiviral agentsPatientsCombinatorial therapyInfectionTherapyWhole-genome sequencingTreatmentImportance of monitoringDe novo emergenceFold increaseRNA-dependent RNA polymeraseNovo emergencePotential benefitsMutationsIndolentSafety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sridhar S, Joaquin A, Bonaparte MI, Bueso A, Chabanon AL, Chen A, Chicz RM, Diemert D, Essink BJ, Fu B, Grunenberg NA, Janosczyk H, Keefer MC, Rivera M DM, Meng Y, Michael NL, Munsiff SS, Ogbuagu O, Raabe VN, Severance R, Rivas E, Romanyak N, Rouphael NG, Schuerman L, Sher LD, Walsh SR, White J, von Barbier D, de Bruyn G, Canter R, Grillet MH, Keshtkar-Jahromi M, Koutsoukos M, Lopez D, Masotti R, Mendoza S, Moreau C, Ceregido MA, Ramirez S, Said A, Tavares-Da-Silva F, Shi J, Tong T, Treanor J, Diazgranados CA, Savarino S. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. The Lancet Infectious Diseases 2022, 22: 636-648. PMID: 35090638, PMCID: PMC8789245, DOI: 10.1016/s1473-3099(21)00764-7.Peer-Reviewed Original ResearchConceptsHigh-dose groupLow-dose groupMedium-dose groupGeometric mean titresAdverse eventsRecombinant protein vaccineCOVID-19 vaccineSecond vaccinationSARS-CoV-2Day 36Antigen doseAdverse reactionsProtein vaccineMedical conditionsVaccine-related serious adverse eventsHigh-risk medical conditionsInteractive response technology systemAntibody geometric mean titresPre-existing medical conditionsCandidate vaccine formulationsCoV2 preS dTMPrevious phase 1Primary immunogenicity objectivePseudovirus neutralization assayUnsolicited adverse eventsDolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment
2021
High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities
Ogbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.Peer-Reviewed Original ResearchConceptsHIV testing dataNon-pregnant individualsHIV detection rateTertiary facilityPrevention interventionsJohn F. Kennedy Medical CenterHospital-based retrospective analysisSignificant public health challengeStudy periodAnnual diagnosis ratePre-exposure prophylaxisPositive HIV testLarge tertiary hospitalCase detection ratePublic health challengeYears of ageNational prevalence estimatesDetection rateHIV/AIDSAntenatal clinicHIV testHIV testingTertiary hospitalPregnant womenUNAIDS 95Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field
Adeiza MA, Wachekwa I, Nuta C, Donato S, Koomson F, Whitney J, Plyler C, Kerr L, Sackey G, Dunbar E, Talbert-Slagle K, Klar R, Marsh RH, Caldwell S, Toomey J, Ogbuagu O. Gaps and Opportunities in HIV Service Delivery in High Volume HIV Care Centers in Liberia: Lessons From the Field. Annals Of Global Health 2021, 87: 115. PMID: 34900615, PMCID: PMC8622325, DOI: 10.5334/aogh.3246.Commentaries, Editorials and LettersConceptsHIV service deliveryAntiretroviral therapyOverall health system strengtheningHuman immunodeficiency virus (HIV) infectionHealth systemNon-physician healthcare workersCascade of careCombination prevention approachesHIV care centersViral load suppressionImmunodeficiency virus infectionEbola virus disease outbreakNew HIV infectionsQuality of lifePublic health impactHealth system strengtheningVirus disease outbreakResponsive health systemART initiationHIV workforceUndiagnosed HIVViral suppressionUNAIDS targetsUniversal health coverageHIV infectionQualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV
Tuan JJ, Zapata H, Critch‐Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti‐SARS‐CoV‐2 spike protein immunogenicity (QUASI) after COVID‐19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineCOVID-19 vaccinationFirst doseSeroconversion ratesSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionYale New Haven Health SystemPrior COVID-19 infectionSyndrome coronavirus 2 infectionSafe COVID-19 vaccineIntegrase strand transfer inhibitorsAnti-spike IgGPositive IgG responseTwo-dose seriesCoronavirus 2 infectionVaccine-induced immunityDurability of protectionCOVID-19 infectionStrand transfer inhibitorsAntiretroviral regimenBNT162b2 vaccineNew seroconversionsPositive IgGQualitative antibodyFacing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative
Marsh RH, Plyler C, Miller M, Klar R, Adeiza M, Wachekwa I, Koomson F, Garlo JL, Kruah K, Lake SC, Matte R, Cook R, Maweu D, Kerr L, Ogbuagu O, Talbert-Slagle K, Dahn B. Facing COVID-19 in Liberia: Adaptations of the Resilient and Responsive Health Systems Initiative. Annals Of Global Health 2021, 87: 101. PMID: 34707981, PMCID: PMC8499715, DOI: 10.5334/aogh.3245.Commentaries, Editorials and LettersConceptsCommunity health worker involvementHealth system initiativesHealth worker involvementCOVID-19 pandemicHealth service impactsResponsive health systemHIV targetsHealth outcomesPatient volumeHealth workforceTelehealth servicesHealth systemOngoing educationService deliveryCOVID-19Safety protocolsClinical didacticsPandemicDirect service deliveryWorkforce programsFourth yearTraining impactEducational programsDeliveryHIVSafety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021, 385:239-250.Peer-Reviewed Original Research